To Boost Productivity, India’s Advinus, Takeda Team Up For R&D Across Therapies
This article was originally published in PharmAsia News
Takeda looks to ride on Advinus’ broad early-stage pipeline while also generating new INDs.
You may also be interested in...
MUMBAI - Almost a year after naming former Roche executive Shankar Suryanarayanan as head of its Indian operations, Japan's largest drug maker Takeda has unveiled "medium- to long-term strategies" for its business expansion - one of which is to launch its products in the burgeoning Indian market
Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News (Part 1 of 2)
Advinus Therapeutics CEO Rashmi Barbhaiya is one of the most visible figures in today's pharmaceutical research in India. Beyond a deep knowledge of life sciences, he is famous for the daring - if not risky - moves that he made nine years ago, when he shifted from his top job in U.S.-based Bristol-Myers Squibb to head Ranbaxy's R&D team, and then spearheaded the research ambitions of India's biggest corporate conglomerate - The Tata group.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.